BIORBIORA THERAPEUTICS, INC.

Nasdaq bioratherapeutics.com


$ 0.74 $ 0.03 (3.79 %)    

Friday, 14-Jun-2024 15:59:31 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 0.7474
$ 0.72
$ 0.00 x 0
$ 0.00 x 0
$ 0.71 - $ 0.75
$ 0.48 - $ 4.69
150,843
na
21.9M
$ 1.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-18-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biora-therapeutics-says-company-did-not-regain-compliance-with-nasdaqs-mvls-rule-by-june-10-2024

-SEC Filing

 biora-therapeutics-says-notified-co-that-its-securities-were-subject-to-delisting-from-nasdaq-unless-company-timely-requests-hearing-before-panel

-SEC Filing-SEC Filing

 biora-therapeutics-to-present-on-the-biojet-systemic-oral-delivery-platform-at-the-next-gen-peptide-formulation--delivery-summit-2024

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...

 biora-therapeutics-to-present-clinical-data-on-device-function-of-the-navicap-platform-at-digestive-disease-week-2024

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled...

 hc-wainwright--co-reiterates-buy-on-biora-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 pr...

 biora-therapeutics-q1-2024-gaap-eps-014-beats-045-estimate-sales-542000k

Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(...

 biora-therapeutics-to-present-clinical-data-on-device-function-of-the-navicap-oral-delivery-platform-at-digestive-disease-week-2024

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...

 biora-therapeutics-announces-completion-of-multiple-ascending-dose-cohorts-for-clinical-trial-of-bt-600

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024S...

 biora-therapeutics-announces-new-patent-covering-its-biojet-liquid-jet-delivery-technology

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issua...

 biora-therapeutics-achieves-interim-results-for-clinical-trial-of-bt-600-advancing-navicap-platform-development

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All Na...

 why-nuvve-holding-shares-are-trading-lower-by-around-30-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expect...

 earlier-biora-therapeutics-announced-a-6m-registered-direct-offering-of-5454548-shares-of-common-stock-at-a-price-of-110-per-share

Biora Therapeutics, Inc.